GlassScriptPhysician profile
John Raymond Ernst
NPI 1134470388
$2,551.69
in general payments reported to CMS, 2019-2025
17 companies · $901 in 2025
The $901 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $475 · 2023: $465 · 2024: $711 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.65 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,021.74 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $327.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $222.03 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $180.69 | 2022-2025 | Dupixent |
| Amgen INC. | $142.61 | 2022-2023 | Tezspire |
| Mylan Specialty L.P. | $104.41 | 2022-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Verona Pharma, INC. | $91.62 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $71.58 | 2025 | Dawnzera, Donidalorsen |
| Takeda Pharmaceuticals U.S.A., INC. | $63.32 | 2023-2024 | Cuvitru |
| Csl Behring | $46.75 | 2025 | Hizentra, Andembry |
| Kaleo, INC. | $44.78 | 2022 | |
| Alk-Abello, INC | $39.33 | 2023 | Ragwitek, Odactra, Grastek |
| Octapharma USA, INC. | $36.00 | 2022-2023 | Panzyga |
| Ars Pharmaceuticals Operations, INC. | $22.61 | 2025 | Neffy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $20.94 | 2022 | |
| Pfizer INC. | $17.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.